Abstract
In response to the global coronavirus disease 2019 (COVID-19) pandemic, 2 messenger RNA (mRNA) COVID-19 vaccines were developed and authorized for use.1,2 Adverse events following immunization (AEFI) have occurred after receipt of these vaccines to include anaphylaxis that is estimated to occur at a rate of 2.5 to 11 cases per 1 million doses.3 Several studies have found tolerance to vaccine challenge in these individuals, suggesting the reactions are likely not immunoglobulin (Ig)E driven.4,5 The Centers for Disease Control and Prevention now considers nonsevere, immediate, allergic-type reactions after a dose of a COVID-19 vaccine a precaution, not a contraindication, to a subsequent dose of the same vaccine.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
